Stock data
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS) reported net income of -US$6.00M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$11.91M | -US$6.00M | — |
| 2024 | — | — | -US$1.28M | -US$1.39M | — |
| 2023 | — | — | -US$0.75M | -US$0.78M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$20.17M | — |
| 2026-03-31 | — | -US$35.06M | — |
| 2025-12-31 | — | -US$1.16M | — |
| 2025-09-30 | — | -US$1.78M | — |
| 2025-06-30 | — | -US$2.66M | — |
| 2025-03-31 | — | -US$0.40M | — |
| 2024-12-31 | — | -US$0.31M | — |
| 2024-09-30 | — | -US$0.33M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.